The effect of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women.
The serum cholesterol and triglyceride concentrations of 84 postmenopausal women both before and after 2, 6 and 12 months therapy with various regimens of hormone therapy were measured. There was little alteration in mean serum cholesterol concentration with cyclical oestrogens but both sequential mestranol and norethisterone and sequential oestradiol valerate and norgestrel significantly reduced the mean serum cholesterol concentration to a level similar to that found in age-matched premenopausal women. There was a small and sometimes significant rise in serum triglyceride concentration with cyclical oestrogens. Sequential mestranol and norethisterone significantly elevated serum triglyceride levels, but sequential oestradiol valerate and norgestrel significantly depressed them. The results suggest that the progestogenic agent norgestrel has an important role to play in reducing both serum cholesterol and triglyceride levels, and that the sequential preparations, by virtue of their greater cholesterol lowering effect, should perhaps be preferred to cyclical oestrogens.
D002784:Cholesterol / Q000097:blood*; D004338:Drug Combinations; D004958:Estradiol / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D004970:Estrone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008656:Mestranol / Q000627:therapeutic use; D009640:Norethindrone / Q000627:therapeutic use; D009644:Norgestrel / Q000627:therapeutic use; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
D004338:Drug Combinations; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D014280:Triglycerides; D004970:Estrone; D009644:Norgestrel; D004958:Estradiol; D002784:Cholesterol; D008656:Mestranol; D009640:Norethindrone